CClinicalTrials.gg
Not yet recruitingNCT05937503Updated Jul 18, 2023

Efficiency of Manual Therapy on Central Sensitization in Patients With Nonspecific Chronic Back Pain

An interventional study of manual therapy and conventional physiotherapy in Central Sensitization and Manual Therapy, sponsored by Atılım University. Not yet recruiting at 2 sites in Turkey. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Atılım University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2023, 3 years 1 month ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Study summary

Central sensitization (CS) is defined as the increased responsiveness of nociceptive neurons in the central nervous system to normal or subthreshold afferent input. CS has been proposed as an underlying mechanism of chronic pain in musculoskeletal disorders including low back pain (LBP).

The aim of this study is to investigate the effect of manual therapy on central sensitization in patients with nonspecific chronic LBP.

Read the detailed description

A total of 40 LBP patients aged between 24-64 with CSS will be randomized into two groups. The manual therapy group will receive a 4-week manual therapy (two sessions/week) plus the conventional physiotherapy program, while the control group will only receive conventional physiotherapy. Before and after the interventions pain intensity (VAS), and scores of three questionnaires: Oswestry Disability Index (ODI), Central Sensitization Inventory (CSI), and the 36-item Short Form Health Survey Questionnaire (SF-36) will be recorded.The outcomes of the study will be analyzed by appropriate statistical methods.

02

Conditions studied

  • Central Sensitization
  • Manual Therapy

Browse trials for

Keywords

  • central sensitization
  • manual therapy
  • non-specific low back pain
03

In context

Back Pain

2,373 studies on the registry are indexed under Back Pain; 284 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 1,941 interventional studies indexed under Back Pain.

Browse Back Pain studies →

Lead sponsor

Atılım University is the lead sponsor of 35 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • non-spesific low back pain patients with pain longer than 12 weeks
  • aged between 20-64 years male and female participants

Exclusion criteria

Exclusion Criteria:

  • concomitant disease that would interfere with treatment
  • pregnancy
  • have had any spinal surgery or fracture
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Manual therapy

    Manual therapy group

    Other: manual therapy · Other: conventional physiotherapy

  • Other
    Conventional physiotherapy

    Conventional physiotherapy group

    Other: manual therapy · Other: conventional physiotherapy

Interventions

  • Othermanual therapy

    The manual therapy group will receive a 4-week manual therapy plus conventionel physiotherapy.

    Also known as: conventional physiotherapy

  • Otherconventional physiotherapy

    Control group will only receive conventionel physiotherapy intervention.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    A 10 cm Visual Analog Scale will be used to determine the severity of pain, with numbers ranging from "0" (no pain) to "10" (unbearable pain)

    Time frame: Up to one month

  2. Central Sensitization

    Central Sensitization Inventory (CSI) scale will be used severity of central sensitization.The total score range of the scale, which consists of a total of 25 questions, is between 0-100 points. Central sensitization with a score of 40 and above is considered positive. An increase in the total score indicates an increase in the level of central sensitization.

    Time frame: Up to one month

Secondary outcomes

  1. Oswestry Disability Index

    Oswestry Disability Index (ODI) will be used to measure disability level

    Time frame: Up to one month

  2. Health Survey

    36-item Short Form Health Survey Questionnaire (SF-36) will be used

    Time frame: Up to one month

  3. Hospital Anxeity and depresssion

    Hospital Anxeity and Depression Scale will be used. The cut-off points for caseness of anxiety or depression is 8/21 for anxiety or depression. For anxiety (HADS-A) this gave a specificity of 0.78 and a sensitivity of 0.9. For depression (HADS-D) this gave a specificity of 0.79 and a sensitivity of 0.83. The scores of the scale are as follows: 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)

    Time frame: Up to one month

07

Study locations

2 sites
  • Naime Ulug
    Ankara, Select State 06830, Turkey
  • Atılım University
    Ankara, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05937503
Lead sponsor
Atılım University
Responsible party
NAİME ULUG (PhD., Atılım University) — Principal investigator
First posted
Jul 10, 2023
Start date
Jul 17, 2023 (estimated)
Primary completion
Aug 30, 2023 (estimated)
Completion
Aug 30, 2023 (estimated)
Last update
Jul 18, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion